zenagamtide SC (NN9487 SC) / Novo Nordisk - LARVOL DELTA

AMAZE 10: A Research Study Investigating How Well the Medicine NNC0487-0111 Helps People in Japan With Excess Body Weight Lose Weight (clinicaltrials.gov) - P3 | N=400 | Recruiting | Sponsor: Novo Nordisk A/S

New P3 trial • Genetic Disorders • Obesity

AMAZE 12: A Research Study Investigating How Well the Medicine NNC0487-0111 Helps People With Excess Body Weight Maintain Their Weight Loss (clinicaltrials.gov) - P3 | N=606 | Active, not recruiting | Sponsor: Novo Nordisk A/S | Recruiting ➔ Active, not recruiting

Enrollment closed • Genetic Disorders • Obesity

A Research Study to See How NNC0487-0111 Affects the Body's Energy Use After a Weight Loss in Adults Living With Obesity, Compared to a Low-calorie Diet or Placebo (clinicaltrials.gov) - P1 | N=120 | Recruiting | Sponsor: Novo Nordisk A/S

New P1 trial • Genetic Disorders • Obesity

…Novo Nordisk is planning to initiate a phase 3 development program with zenagamtide for adults with type 2 diabetes in H2 2026 (Novo Nordisk Press Release)

New P3 trial • Type 2 Diabetes Mellitus

Novo Nordisk…announced new clinical data from the positive phase 2 trial of investigational zenagamtide….presented at the 2026 Scientific Sessions of the American Diabetes Association (ADA) (Novo Nordisk Press Release) - "...Results from the phase 2 dose finding study included the evaluation of six subcutaneous doses of zenagamtide (ranging from 0.4 mg to 40 mg) versus matched placebo in 262 adults with type 2 diabetes inadequately controlled (A1C 7.0–10.0%) on metformin, with or without an SGLT2 inhibitor. The study met its primary endpoint of change in A1C across all doses and also key supportive secondary endpoint of change in body weight (with doses 1.5 mg and greater) with zenagamtide versus placebo after 36 weeks....Study...showed statistically significant reductions in blood sugar in adults with type 2 diabetes compared to placebo, with up to 89.1% achieving A1C below 7%. Additionally, participants treated with zenagamtide showed body weight loss up to 14.6% at week 36 with the highest dose investigated, 40 mg."

P2 data • Type 2 Diabetes Mellitus

Novel Amylin-Based Therapies for Weight Management in Adults With Overweight or Obesity Without Diabetes: A Network Meta-Analysis. (PubMed, Endocrinol Diabetes Metab) - "Novel ABTs, such as HiD amycretin, CagriSema and eloralintide, may induce substantial short- to medium-term weight loss but may also increase GI AEs; given sparse, low-certainty data, these findings are preliminary and require confirmation in larger trials."

Clinical • Journal • Retrospective data • Review • Constipation • Diabetes • Gastroenterology • Gastrointestinal Disorder • Genetic Disorders • Metabolic Disorders • Obesity

AMAZE 3: A Research Study Investigating How Well the Medicine NNC0487-0111 Helps People With Excess Body Weight and Obstructive Sleep Apnoea Not Treated With Positive Airway Pressure Lose Weight and Improve Sleep Apnoea (clinicaltrials.gov) - P3 | N=300 | Recruiting | Sponsor: Novo Nordisk A/S | Not yet recruiting ➔ Recruiting

Enrollment open • Genetic Disorders • Obesity • Respiratory Diseases • Sleep Apnea • Sleep Disorder

AMAZE 4: A Research Study Investigating How Well the Medicine NNC0487-0111 Helps People With Excess Body Weight and Obstructive Sleep Apnoea Treated With Positive Airway Pressure Lose Weight and Improve Sleep Apnoea (clinicaltrials.gov) - P3 | N=300 | Recruiting | Sponsor: Novo Nordisk A/S | Not yet recruiting ➔ Recruiting

Enrollment open • Genetic Disorders • Obesity • Respiratory Diseases • Sleep Apnea • Sleep Disorder

NN9490-8028: AMAZE 8: A research study investigating how well the medicine NNC0487-0111 compared to semaglutide helps people with excess body weight and type 2 diabetes lose weight (clinicaltrialsregister.eu) - P2/3 | N=85 | Not yet recruiting | Sponsor: Novo Nordisk A/S

New P2/3 trial • Diabetes • Genetic Disorders • Metabolic Disorders • Obesity • Type 2 Diabetes Mellitus

AMAZE 6: A Research Study Investigating How Well the Medicine NNC0487-0111 Helps People With Excess Body Weight and Knee Osteoarthritis Lose Weight and Reduce Pain (clinicaltrials.gov) - P3 | N=400 | Recruiting | Sponsor: Novo Nordisk A/S | Not yet recruiting ➔ Recruiting

Enrollment open • Genetic Disorders • Immunology • Obesity • Osteoarthritis • Pain • Rheumatology

AMAZE 4: A Research Study Investigating How Well the Medicine NNC0487-0111 Helps People With Excess Body Weight and Obstructive Sleep Apnoea Treated With Positive Airway Pressure Lose Weight and Improve Sleep Apnoea (clinicaltrials.gov) - P3 | N=300 | Not yet recruiting | Sponsor: Novo Nordisk A/S

New P3 trial • Genetic Disorders • Obesity • Respiratory Diseases • Sleep Apnea • Sleep Disorder

AMAZE 3: A Research Study Investigating How Well the Medicine NNC0487-0111 Helps People With Excess Body Weight and Obstructive Sleep Apnoea Not Treated With Positive Airway Pressure Lose Weight and Improve Sleep Apnoea (clinicaltrials.gov) - P3 | N=300 | Not yet recruiting | Sponsor: Novo Nordisk A/S

New P3 trial • Genetic Disorders • Obesity • Respiratory Diseases • Sleep Apnea • Sleep Disorder

NN9490-8024: AMAZE 2: A research study investigating how well the medicine NNC0487-0111 helps people with excess body weight and type 2 diabetes lose weight (clinicaltrialsregister.eu) - P2/3 | N=80 | Not yet recruiting | Sponsor: Novo Nordisk A/S

New P2/3 trial • Diabetes • Genetic Disorders • Metabolic Disorders • Obesity • Type 2 Diabetes Mellitus

NN9490-8021: AMAZE 1: A research study investigating how well the medicine NNC0487-0111 helps people with excess body weight lose weight (clinicaltrialsregister.eu) - P2/3 | N=270 | Not yet recruiting | Sponsor: Novo Nordisk A/S

New P2/3 trial • Genetic Disorders • Obesity

AMAZE 12: A Research Study Investigating How Well the Medicine NNC0487-0111 Helps People With Excess Body Weight Maintain Their Weight Loss (clinicaltrials.gov) - P3 | N=600 | Recruiting | Sponsor: Novo Nordisk A/S | Not yet recruiting ➔ Recruiting

Enrollment open • Genetic Disorders • Obesity

Novo Nordisk to present new semaglutide data on ‘food noise’, body composition and cardiovascular benefits, as well as pipeline data at the EASD diabetes congress (GlobeNewswire) - "The INFORM real-world evidence study shows impact of semaglutide on reducing ‘food noise’, and the STEP UP clinical trial highlights semaglutide’s effect on control of eating and body composition after losing weight; Next-generation obesity treatment cagrilintide demonstrates promise as standalone therapy (REDEFINE 1); data also being presented on amycretin; The first head-to-head real-world study, REACH shows superiority of Ozempic versus dulaglutide on cardiovascular events such as heart attack and stroke."

Clinical data • Cardiovascular • Obesity • Type 2 Diabetes Mellitus

AMAZE 6: A Research Study Investigating How Well the Medicine NNC0487-0111 Helps People With Excess Body Weight and Knee Osteoarthritis Lose Weight and Reduce Pain (clinicaltrials.gov) - P3 | N=400 | Not yet recruiting | Sponsor: Novo Nordisk A/S | N=220 ➔ 400

Enrollment change • Trial initiation date • Genetic Disorders • Immunology • Obesity • Osteoarthritis • Pain • Rheumatology

NN9490-8559: AMAZE 12: A research study investigating how well the medicine NNC0487-0111 helps people with excess body weight maintain their weight loss (clinicaltrialsregister.eu) - P2/3 | N=235 | Recruiting | Sponsor: Novo Nordisk A/S

New P2/3 trial • Genetic Disorders • Obesity

NN9490-8025: AMAZE 3: A research study investigating how well the medicine NNC0487-0111nhelps people with excess body weight and obstructive sleep apnoea not treated with positive airwaynpressure lose weight and improve sleep apnoea (clinicaltrialsregister.eu) - P2/3 | N=125 | Not yet recruiting | Sponsor: Novo Nordisk A/S | N=90 ➔ 125

Enrollment change • Genetic Disorders • Obesity • Respiratory Diseases • Sleep Apnea • Sleep Disorder

AMAZE 5: A Research Study Investigating How Well the Medicine NNC0487-0111 Helps People With Excess Body Weight and Knee Osteoarthritis Lose Weight and Reduce Pain (clinicaltrials.gov) - P3 | N=400 | Recruiting | Sponsor: Novo Nordisk A/S | Not yet recruiting ➔ Recruiting | N=220 ➔ 400

Enrollment change • Enrollment open • Trial initiation date • Genetic Disorders • Immunology • Obesity • Osteoarthritis • Pain • Rheumatology

A Research Study Looking at How NNC0487-0111 Affects Food Intake, Appetite and Metabolism After Meals in People With Obesity (clinicaltrials.gov) - P1 | N=120 | Recruiting | Sponsor: Novo Nordisk A/S | Not yet recruiting ➔ Recruiting

Enrollment open • Genetic Disorders • Obesity

AMAZE 2: A Research Study Investigating How Well the Medicine NNC0487-0111 Helps People With Excess Body Weight and Type 2 Diabetes Lose Weight (clinicaltrials.gov) - P3 | N=630 | Recruiting | Sponsor: Novo Nordisk A/S | Not yet recruiting ➔ Recruiting

Enrollment open • Diabetes • Genetic Disorders • Metabolic Disorders • Obesity • Type 2 Diabetes Mellitus

NN9490-8293: AMAZE 4: A research study investigating how well the medicine NNC0487-0111 helps people with excess body weight and obstructive sleep apnoea treated with positive airway pressure lose weight and improve sleep apnoea (clinicaltrialsregister.eu) - P2/3 | N=115 | Not yet recruiting | Sponsor: Novo Nordisk A/S | N=55 ➔ 115

Enrollment change • Genetic Disorders • Obesity • Respiratory Diseases • Sleep Apnea • Sleep Disorder

AMAZE 2: A Research Study Investigating How Well the Medicine NNC0487-0111 Helps People With Excess Body Weight and Type 2 Diabetes Lose Weight (clinicaltrials.gov) - P3 | N=630 | Not yet recruiting | Sponsor: Novo Nordisk A/S

New P3 trial • Diabetes • Genetic Disorders • Metabolic Disorders • Obesity • Type 2 Diabetes Mellitus

AMAZE 5: A Research Study Investigating How Well the Medicine NNC0487-0111 Helps People With Excess Body Weight and Knee Osteoarthritis Lose Weight and Reduce Pain (clinicaltrials.gov) - P3 | N=220 | Not yet recruiting | Sponsor: Novo Nordisk A/S

New P3 trial • Genetic Disorders • Immunology • Obesity • Osteoarthritis • Pain • Rheumatology • CRP